106
Participants
Start Date
October 1, 2021
Primary Completion Date
October 1, 2024
Study Completion Date
October 1, 2024
Magrolimab
Administered intravenously
Docetaxel
Administered intravenously
Centre de Lutte Contre le Cancer (CLCC) - Centre Antoine Lacassagne (CAL) - Site Est, Nice
Hospital del Mar, Barcelona
Hospital Quironsalud Barcelona, Barcelona
Hospital De La Santa Creu I Sant Pau, Barcelona
Hopital Nord AP-HM, Marseille
Centre Georges François Leclerc, Dijon
Hospital Universitario de Jaen, Jaén
Hospital General Universitario Gregorio Maranon, Madrid
MD Anderson Cancer Center, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital HM Sanchinarro, Madrid
Hospital Regional Universitario de Malaga, Málaga
Charleston Oncology, Charleston
Southeastern regional Medical Center, Newnan
University Center and Blood Center,LLC., Athens
Clinica Universidad de Navarra, Pamplona
Tallahassee Memorial Healthcare Cancer Center, Tallahassee
Institut Bergonie, Bordeaux
University of Miami, Deerfield Beach
Hospital Universitario Virgen Macarena, Seville
Hospital Universitario Virgen del Rocio, Seville
Hospital Universitari i Politecnic La Fe, Valencia
University of Michigan, Ann Arbor
University of Iowa Hospitals & Clinics, Iowa City
Virginia Piper Cancer Center (Alliant Health), Saint Paul
Centre Hospitalier Regional Universitaire de Lille, Lille
Orchard Healthcare Research Inc, Skokie
Centre Hospitalier Lyon-Sud, Pierre-Bénite
Centre LÃon BÃrard Centre RÃgional de Lutte Contre Le Cancer, Lyon
Hôpital de la Pitié Salpétrière, Paris
Mary Crowley Cancer Research, Dallas
MD Anderson Cancer Center, Dallas
Saint Alphonsus Cancer Institute Caldwell, Caldwell
Huntsman Cancer Institute, University of Utah, Salt Lake City
Cancer Treatment Centers of America, Goodyear
Comprehensive Cancer Centers of Nevada- Twain Office, Las Vegas
Providence Saint John's Health Center, Santa Monica
UC San Diego Moores Cancer Center, La Jolla
St. Jude Hospital Yorba dba St. Joseph Heritage Healthcare, Santa Rosa
Oregon Health & Science University, Portland
Medical Oncology Associates,PS (dba Summit Cancer Center) (includes IP Shipment), Spokane
Astera Cancer Care, East Brunswick
Institut de Cancérologie de l'Ouest (ICO) - Saint-Herblain, Saint-Herblain
Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz
Instytut Centrum Zdrowia Matki Polki, Lodz
Wojewodzki Szpital Specjalistyczny w Siedlcach, Siedlce
Instituto de Investigacion Oncologica Vall de Hebron, Barcelona
Barts Health NHS Trust, London
Guy's and St Thomas' NHS Foundation Trust, London
Lead Sponsor
Gilead Sciences
INDUSTRY